Active Ingredient(s):Drotrecogin Alfa FDA Approved: * November 21, 2001 Pharm Company: *LILLY Category:Anti-Inflammatory
Drotrecogin alfa (activated) (Xigris, marketed by Eli Lilly and Company) is a recombinant form of human activated protein C that has anti-thrombotic, anti-inflammatory, and profibrinolytic properties. Drotrecogin alpha (activated) belongs to the class of serine proteases. Drotrecogin alfa has not been found to improve outcomes in people with severe sepsis. The manufacturer's aggressive strategies in marketing its use in severe sepsis have been criticized. On October 25, 20...
* May have multiple approval dates, manufacturers, or labelers. 3 Discussions